Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive‐stage small‐cell lung cancer: A retrospective analysis of survival outcomes
Jinmin Han, Ying Hua, Xue Wu, Xiufeng Tang, Chengxin Liu · 2025
Read Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive‐stage small‐cell lung cancer: A retrospective analysis of survival outcomes by Jinmin Han, Ying Hua, Xue Wu, Xiufeng Tang, Chengxin Liu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750307.txt.
Description
Jinmin Han and four co-authors weigh, in 2025 records work, three care blends for wide-spread small-cell lung cancer. Whether chest rays add worth atop drug-plus-guard care was unsettled. Two hundred six patients split into guard-based care and drug-plus-ray care, the first split again by whether rays joined.
The full three-way blend lived longest at the mid mark, past drug-plus-guard alone; drug-plus-ray alone sat in the mid. Tumour shrink rates ran near alike across arms, a touch ahead in the full blend. No gap hit the firm bar. The team backs chest rays as fit in the guard era, and plain drug-plus-ray where means are thin.
Catalog record
| CREATOR | Jinmin Han, Ying Hua, Xue Wu, Xiufeng Tang, Chengxin Liu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |